EDAP Edap Tms S.A. ADS

EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023

EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023

Company to host conference call and webcast on Thursday, November 9th at 8:30am EDT

LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th, 2023, before the markets open on Thursday, November 9th, 2023.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary. The call will be held at 8:30am EDT on Thursday, November 9th, 2023. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date: Thursday, November 9th
Time: 8:30am EDT
Domestic: 1-877-451-6152
International: 1-201-389-0879
Passcode: 13741382
CallMeTM (active 15 minutes prior to conference call)
Webcast:

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit ,  and .

Company Contact

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

John Fraunces

LifeSci Advisors, LLC

(917) 355-2395





 

 



EN
26/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE

EDAP Reports First Quarter 2025 Financial Results

EDAP Reports First Quarter 2025 Financial Results           Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World’s First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global lea...

 PRESS RELEASE

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025 Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, ...

 PRESS RELEASE

EDAP Announces Positive Results from the FARP Randomized Controlled Tr...

EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up. AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), ...

 PRESS RELEASE

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 12...

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ProstateFocal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasetsFocal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications...

 PRESS RELEASE

EDAP Announces Significant Presence of Focal One® at the Upcoming 120t...

EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical prostatectomy as a first-line treatment for prostate cancer Presentation on the first ever remote transatlantic Focal One Robotic HIFU procedure will be given by Ruben Olivares, MD, Urologic Surgeon at the Cleveland Clinic, at the AUA session of the Engi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch